SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced it has signed a revenue-producing agreement with one of the world’s largest pharmaceutical companies to provide assay development as well as sample testing services.
This pharmaceutical customer has a unique need to measure how their drugs interact with a key biomarker in the human body by measuring antibody levels. SQI is in a unique position with its multiplexing technology to develop an automated, multiplexed test to measure these drug-biomarker interactions.
In addition, because of the sensitive timeframe of this project, the customer has also engaged SQI to provide contract research services to provide the analytical sample testing, which could be in excess of 1000 samples for which the customer will be charged a per-sample fee. This testing will be done at SQI’s state-of-the-art facility in Toronto.
“We are excited to sign this agreement with such a large and respected institution in the pharmaceutical and biotechnology space,” said Andrew Morris, CEO of SQI Diagnostics. “This also presents the largest customer to date that has engaged SQI to provide sample testing services which is a new and burgeoning business for SQI.”
“This agreement will open the door for SQI to be a preferred vendor for this type of assay development and testing service, certainly for this customer and hopefully for other global pharmas as well.”
In addition to this important agreement we expect to continue to issue more positive commercial news prior to year-end, including the shipping of a sqidlite instrument and product-validation kits to our cardiac biomarker customer and at least 1 other large drug development customer prior to year-end.
